Amylx Pharmaceuticals Inc vs Lemonade Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $24.06 (market cap $2.64B), while Lemonade Inc trades at $51.95 (market cap $4.09B). The key difference: Lemonade Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | LMND | |
|---|---|---|
Market Cap | $2.64B | $4.09B |
Sector | Health | Financials |
52-Week High | $24.19 | $96.57 |
52-Week Low | $7.82 | $47.38 |
Enterprise Value | $2.39B | $3.95B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Lemonade (LMND) trades at $52.68, down 0.49% on the day, with technical indicators showing a bearish bias. The company reported Q2 2026 revenue growth of 79% year-over-year and has beaten EPS estimates for three consecutive quarters, yet remains unprofitable with a net income margin of -22.43% in 2025. Recent news highlights management's presentation at an Oppenheimer conference and ongoing expansion of renters insurance products.
The outlook is mixed; accelerating premium growth and a path to positive adjusted EBITDA by Q4 2026 offer upside potential, but high valuation multiples, persistent losses, and bearish technical signals present significant risks. Analyst consensus is evenly split, reflecting uncertainty around the profitability timeline.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →